Turquie - turc - TİTCK (Türkİye İlaç Ve Tibbİ Cİhaz Kurumu)

vİtalİs saĞlik ÜrÜnlerİ daniŞmanlik ve tİc. a.Ş. - flumetasone - flumetasone

Turquie - turc - TİTCK (Türkİye İlaç Ve Tibbİ Cİhaz Kurumu)

santa farma İlaÇ san. a.Ş. - hamamelis virginiana distilatı -

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

diversey australia pty. limited - ethoxylated lanolin; sorbitol; propylene glycol - topical solution/suspension - ethoxylated lanolin ungrouped active 3.0 g/l; sorbitol carbohydrate active 600.0 g/l; propylene glycol solvent active 200.0 g/l - dermatological preps. - dairy cattle | bovine | breeders | calves | dairy cow | growers | lactating cow | milking cow - enhance teat condition

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - lanolin 2.611%{relative} equivalent to 3% w/w; light liquid paraffin 79.9744%{relative} equivalent to 91.9% w/w - bath oil - active: lanolin 2.611%{relative} equivalent to 3% w/w light liquid paraffin 79.9744%{relative} equivalent to 91.9% w/w excipient: oxybenzone polyethylene glycol 400 dilaurate

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - lanolin 0.6%; light liquid paraffin 15.9% - lotion - active: lanolin 0.6% light liquid paraffin 15.9% excipient: carbomer docusate sodium glyceryl 1-monostearate lauromacrogol 200 macrogol stearate 2000 methyl hydroxybenzoate polyethylene glycol 400 dilaurate propyl hydroxybenzoate propylene glycol purified water trolamine

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

crackerjack investments ltd - allyl isothiocyanate 1.2%; eucalyptus oil 2.35%; menthol 7.5%; methyl salicylate 36.6% - topical ointment - active: allyl isothiocyanate 1.2% eucalyptus oil 2.35% menthol 7.5% methyl salicylate 36.6%

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - lanolin 3%; light liquid paraffin 91% - bath oil - 3%/91% - active: lanolin 3% light liquid paraffin 91%

États-Unis - anglais - NLM (National Library of Medicine)

savage laboratories a division of fougera pharmaceuticals inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 20 mg in 1 g - nitroglycerin ointment is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it.

États-Unis - anglais - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topic

États-Unis - anglais - NLM (National Library of Medicine)

alcon - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - solution/ drops - 150 mg in 1 ml - for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus ( viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa. a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. hypersensitivity to sulfonamides or to any ingredient of the preparation.